Imugene (ASX:IMU) to proceed to final dose cohort for lung cancer treatment

Company News

by Michael Luu

$620-million cancer treatment provider Imugene (ASX:IMU) has announced that an independent team of researchers have certified that lung cancer drug PD1-Vaxx is safe for human use at 50 micrograms.

This means the company can now advance the Phase I clinical trial of the immunoetherapy candidate to the full and final dosage of 100 micrograms. The tests recorded promising signs of the product’s efficacy, as PD1-Vaxx halted the tumour spread for 3 patients and fully regressed the cancer in one patient.

Imugene has also received the green light from the US Institutional Review Board to commence the Phase I clinical trial of the product at the renowned Mayo Clinic in Phoenix, Arizona.

Shares in Imugene have climbed 11.5 per cent to reach an all-time high of 14 cents

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.